U.S. markets closed
  • S&P Futures

    3,648.25
    -12.75 (-0.35%)
     
  • Dow Futures

    29,106.00
    -97.00 (-0.33%)
     
  • Nasdaq Futures

    11,288.50
    -45.25 (-0.40%)
     
  • Russell 2000 Futures

    1,663.00
    -5.40 (-0.32%)
     
  • Crude Oil

    77.71
    -0.79 (-1.01%)
     
  • Gold

    1,632.00
    -4.20 (-0.26%)
     
  • Silver

    18.24
    -0.10 (-0.56%)
     
  • EUR/USD

    0.9565
    -0.0033 (-0.34%)
     
  • 10-Yr Bond

    3.9640
    +0.0860 (+2.22%)
     
  • Vix

    32.60
    +0.34 (+1.05%)
     
  • GBP/USD

    1.0672
    -0.0059 (-0.55%)
     
  • USD/JPY

    144.7190
    -0.0720 (-0.05%)
     
  • BTC-USD

    18,994.32
    -777.74 (-3.93%)
     
  • CMC Crypto 200

    436.21
    -22.93 (-4.99%)
     
  • FTSE 100

    6,984.59
    -36.36 (-0.52%)
     
  • Nikkei 225

    26,317.10
    -254.77 (-0.96%)
     

Amneal to Report First Quarter 2022 Results on May 4, 2022

·2 min read

BRIDGEWATER, N.J., April 07, 2022--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its first quarter 2022 financial results on Wednesday, May 4, 2022, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on May 4, 2022.

The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com.

To access the call through a conference line, dial (844) 200-6205 (in the U.S.) or (929) 526-1599 (international callers). The access code for the call is 874223.

A replay of the conference call will be posted shortly after the call and will be available for seven days. To access the replay, dial (866) 813-9403 (in the U.S.) or +44 (204) 525-0658 (international callers). The access code for the replay is 097886.

About Amneal

Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals, primarily within the United States. The Company has a diverse portfolio of approximately 250 products in its Generics segment and is expanding across a broad range of complex products and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceutical products focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more, please visit www.amneal.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220407005096/en/

Contacts

Anthony DiMeo
Head of Investor Relations
Anthony.DiMeo@amneal.com